Cost-Effectiveness Analysis in Health (eBook)

A Practical Approach

Peter Muennig, Mark Bounthavong (Autoren)

eBook Download: EPUB

2016 | 3. Auflage
John Wiley & Sons (Verlag)
978-1-119-01128-6 (ISBN)

Infos

The field's bestselling reference, updated with the latest tools, data, techniques, and the latest recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine

Cost-Effectiveness Analysis in Health is a practical introduction to the tools, methods, and procedures used worldwide to perform cost-effective research, Covering every aspect of a complete cost-effectiveness analysis, this book shows you how to find which data you need, where to find it, how to analyze it, and how to prepare a high-quality report for publication, Designed for the classroom or the individual learner, the material is presented in simple and accessible language for those who lack a biostatistics or epidemiology background, and each chapter includes real-world examples and 'tips and tricks' that highlight key information, Exercises throughout allow you to test your understanding with practical application, and the companion website features downloadable data sets for students, as well as lecture slides and a test bank for instructors, This new third edition contains new discussion on meta-analysis and advanced modeling techniques, a long worked example using visual modeling software TreeAge Pro, and updated recommendations from the U,S, Public Health Service's Panel on Cost-Effectiveness in Health and Medicine, This is the second printing of the 3rd Edition, which has been corrected and revised for 2018 to reflect the latest standards and methods,

Cost-effectiveness analysis is used to evaluate medical interventions worldwide, in both developed and developing countries, This book provides process-specific instruction in a concise, structured format to give you a robust working knowledge of common methods and techniques,

• Develop a thoroughly fleshed-out research project
• Work accurately with costs, probabilities, and models
• Calculate life expectancy and quality-adjusted life years
• Prepare your study and your data for publication

Comprehensive analysis skills are essential for students seeking careers in public health, medicine, biomedical research, health economics, health policy, and more, Cost-Effectiveness Analysis in Health walks you through the process from a real-world perspective to help you build a skillset that's immediately applicable in the field,

PETER MUENNIG, MD, MPH, is a professor in the Department of Health Policy and Management at Columbia University,

MARK BOUNTHAVONG, PharmD, MPH is a pharmacoeconomist at the Veterans Affairs San Diego Health Care System and an adjunct faculty member of the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego,

Textauszug

LIST OF TABLES, FIGURES, AND EXHIBITS

Tables

1. 1.1 Hypothetical League Table for a Village in Malawi with a $58,000 Health Budget
2. 2.1 Costs Included in a Cost-Effectiveness Analysis of Free Contraception, Conducted from Three Perspectives
3. 2.2 Hypothetical Differences in Health-Related Quality of Life over 10 Years for Diabetic Women and Women in Perfect Health
4. 2.3 Decision Matrix for Various Cost-Effectiveness Scenarios
5. 4.1 Comparison of Pharmaceutical Benchmark Prices
6. 4.2 Partial List of Costs for Treatment of Influenza Infection
7. 4.3 Common Codes Used to Group Diseases
8. 4.4 MEDPAR Cost Data by DRG for 2011
9. 4.5 Medical Component of the Consumer Price Index 2004–2014, Annual Percentage Change over Previous Year
10. 4.6 Hypothetical and Discounted Costs of a Cohort of 1,000 Elderly Persons over 10 Years
11. 5.1 Probabilities and Costs for Vaccinated and Not Vaccinated (Supportive Care) Strategies
12. 5.2 Calculation of Expected Cost for Each Event Pathway for Vaccination and Supportive Care Strategies
13. 6.1 Number of Deaths due to Influenza Virus Infection, by Age Group
14. 6.2 Deaths, Mean Age of Death due to Influenza Virus Infection, and Life Expectancy for Persons Aged 15 to 65
15. 6.3 Calculating Total Years of Life Lost due to Influenza Virus Infection in the United States
16. 6.4 Total Deaths, Deaths due to Influenza Virus Infection, and Total Survivors in a Cohort of 1 Million 15-Year-Olds
17. 6.5 Total Person-Years Lived by the Cohort of 1 Million 15-Year-Olds
18. 6.6 Person-Years Lived Among the Cohort of 15-Year-Olds, Including and Excluding Deaths due to Influenza Virus Infection
19. 6.7 Age-Specific Mortality Rates, Survivors, and Number of Deaths in the Cohort of 1 Million 15-Year-Old Subjects
20. 6.8 Progression of a Cohort of 10 Women with Breast Cancer over a Six-Year Period
21. 7.1 Example of How an HRQL Score for Influenza Illness May Be Derived Using the EQ-5D
22. 7.2 EQ-5D Preference Score Variation Among Age Categories
23. 8.1 Total Person-Years Lived by the Cohort of 1 Million 15-Year-Olds
24. 8.2 Sum of Person-Years Across Age Groups for the Cohort of 1 Million 15-Year-Olds
25. 8.3 Calculating Life Expectancy at a Given Age
26. 8.4 Abridged Life Table for 2011
27. 8.5 A Quality-Adjusted Life Table
28. 10.1 Simple Summary of Costs Used in a Cost-Effectiveness Model
29. 10.2 Cost-Effectiveness Table
30. 10.3 Example of a Cost-Effectiveness Table
31. 11.1 Calculating the Incidence Rate of Developing Cancer due to Exposure to Radiation in a Two-Year Observation Period, 2011–2012
32. 11.2 Calculating the Age-Adjusted Mortality Rate Using a Hypothetical U.S. Population
33. 11.3 Frequency Distribution of Hypothetical Cholesterol Values Obtained from 100 Subjects
34. 12.1 Datasets Useful for Finding Frequently Needed Cost-Effectiveness Parameters
35. 13.1 Results of the Base-Case Analysis
36. 13.2 Age-Indexed Table for Use in the New Tree
37. 13.3 Base-Case Results for the Markov Model
38. 13.4 Base-Case Results After Applying a 3 Percent Discount Rate
39. 13.5 Results After Terminating Calculations at Age 65 or Older
40. A.1 Comparison Between Vaccinated and Not Vaccinated Strategies
41. A.2 Markov Model Using a Vaccine Effectiveness of 75 Percent
42. B.1 Abridged Life Table for the Total Population, United States, 2011
43. B.2 Abridged Quality-Adjusted Life Table for the Total Population, United States, 2011

Figures

1. 1.1 Example of the Effect of a Health Intervention on the Health States of Patients Admitted to the Emergency Room for an Acute Asthma Attack
2. 1.2 Components of a Cost-Effectiveness Analysis
3. 2.1 Graphical Representation of an HRQL Score
4. 2.2 Difference in Total QALYs Between Women Treated and Not Treated for Diabetes over 10 Years
5. 2.3 Graphical Representation of the Impact of High and Low Numerators and Denominators in Calculating Incremental Cost-Effectiveness Ratios
6. 3.1 Flowchart Indicating the Clinical Course of Influenza Illness
7. 3.2 Flowchart Indicating the Course of Influenza Infection Among Subjects Who Receive a Vaccination
8. 3.3 Probability of Seeing a Doctor Among Subjects Who Receive Vaccination Versus Those Who Receive Supportive Care
9. 3.4 Vaccination Strategy Represented with All Probabilities Filled In
10. 3.5 Vaccination Decision Node
11. 4.1 Partial Flowchart of the Course of the Flu
12. 4.2 Costs Associated with the “Does Not See Doctor” Box
13. 5.1 Decision Tree for Whether to Pursue Public Health School or Write a Novel
14. 5.2 Decision Tree with the Potential for Not Finding a Job After Public Health School
15. 5.3 Example of Two Mutually Exclusive Events
16. 5.4 Probabilities of Outcomes for Patients Receiving the Vaccine Intervention
17. 5.5 Course of Events During an Influenza Season Among Those Receiving Supportive Care Alone
18. 5.6 Course of Events During an Influenza Season Among Those Receiving a Vaccination
19. 5.7 Supportive Care Versus Vaccination Decision (Figure 5.5 and 5.6) Represented as a Decision Analysis Tree
20. 5.8 Event Pathway for Vaccination Versus Supportive Care Represented as a Decision Analysis Tree
21. 5.9 The Expected Probability for Each Terminal Node in the Vaccination and Supportive Care Decision Tree
22. 5.10 The Total Cost for Each Terminal Node in the Vaccination and Supportive Care Decision Tree
23. 5.11 Expected Costs for Each Terminal Node in the Vaccination and Supportive Care Decision Tree
24. 5.12 Total Cost and Probability for All Terminal Nodes in the Vaccination and Supportive Care Decision Tree
25. 5.13 Expected Cost and Outcomes for Each Chance Node in the Vaccinated and Supportive Care Decision Tree
26. 5.14 Calculation for the Expected Cost and Probability for a Patient Who Receives Supportive Care, Becomes Ill, and Sees Doctor
27. 5.15 Expected Costs and Outcomes for Different Chance Nodes in the Vaccinated and Supportive Care Decision Tree
28. 6.1 Markov Model for Influenza Mortality in 15-Year-Olds
29. 6.2 Basic Concept of a Markov Model
30. 6.3 Complete Decision Analysis Tree for Calculating Life Expectancy Using TreeAge Pro
31. 6.4 A Rolled-Back Model Using the Probability of Death for the General U.S. Population
32. 7.1 Trade-off Between the Status Quo Health State and a Gamble
33. 7.2 EQ-5D-5L Form Filled Out by a Patient
34. 7.3 Diabetes Markov Model Depicting Three Health States: Mild, Moderate, and Severe Diabetes
35. 8.1 Year-to-Year Progress of Treated and Untreated Subjects with Leishmaniasis
36. 8.2 Basic Markov Model Used to Calculate Life Expectancy
37. 8.3 Markov Models Designed to Calculate the Life Expectancy of Subjects Receiving the Filmore and Reinkenshein Procedures
38. 8.4 Difference in HRQL Among Subjects Who Received the Filmore or the Reinkenshein Procedure
39. 8.5 Filmore Versus Reinkenshein Model Rolled Back to Reveal Gains in Quality-Adjusted Life Expectancy Associated with Each Strategy
40. 8.6 Filmore Versus Reinkenshein Model with Costs Added
41. 8.7 Filmore Versus Reinkenshein Model with Discounting Added to the HRQL Values
42. 8.8 Filmore Versus Reinkenshein Model Rolled Back
43. 9.1 Sensitivity Analysis Focusing on Structure for the Vaccine Event Pathway
44. 9.2 Sensitivity Analysis Focusing on the Parameter Change (Remains Well) for the Vaccine Event Pathway
45. 9.3 Terminal Branch of the Filmore Arm Represented in Figure 8.3
46. 9.4 Incremental Effectiveness of the Reinkenshein Procedure Relative to the Filmore Procedure over a Range of Risk Ratios
47. 9.5 One-Way Sensitivity Analysis Examining How the Cost of Providing the Influenza Vaccine Influences Intervention
48. 9.6 Two-Way Sensitivity Analysis Comparing Changes in the Efficacy of the Influenza Vaccine and the Incidence of Influenza-Like Illness
49. 9.7 Tornado Diagram Example
50. 9.8 Microsimulation of Individual Patients Through a Decision Path
51. 9.9 Chance of Incurring Any Given Value of a Normally Distributed Variable
52. 9.10 Diabetes Model in Which Values of Each Variable Are Normally Distributed
53. 9.11 The Triangular Distribution
54. 9.12 Other Distributions Used in Monte Carlo Simulations
55. 9.13 Cost-Effectiveness Plane with a Single Simulation
56. 9.14 Hypothetical Results of 100 Simulations on the Cost-Effectiveness Plane
57. 9.15 Cost-Effectiveness Acceptability Curve
58. 9.16 Cost-Effectiveness Acceptability Curve for Exercises 2 and 3
59. 11.1 Nonrandom Error
60. 11.2 Random Error
61. 11.3 Graphical Representation of the 100 Cholesterol Values
62. 11.4 Probability Distribution of the 100 Cholesterol...

Produkt-Details

• Erscheint lt. Verlag: 3.2.2016
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Allgemeines / Lexika
• Themenwelt: Medizin / Pharmazie ► Gesundheitswesen
• Themenwelt: Studium ► Querschnittsbereiche ► Prävention / Gesundheitsförderung
• Themenwelt: Technik
• Themenwelt: Wirtschaft ► Betriebswirtschaft / Management ► Finanzierung
• Schlagworte: Öffentlicher Gesundheitsdienst u. Gesundheitspolitik • analyzing cost effectiveness • Biostatistics • cost-effectiveness analysis guide • Cost-Effectiveness Analysis in Health: A Practical Approach, 3rd Edition • cost-effectiveness analysis methods • cost-effectiveness analysis techniques • cost-effectiveness analysis textbook • epidemiology • Gesundheits- u. Sozialwesen • Health & Social Care • health care analysis • health data analysis • life sciences cost-effectiveness analysis • Mark Bounthavong • medical intervention cost effectiveness • medical intervention evaluation • Medizin • Öffentlicher Gesundheitsdienst u. Gesundheitspolitik • Peter Muennig • public health cost-effectiveness • Public Health Guide • public health modeling • public health program cost-effectiveness analysis • Public Health Services & Policy • statistics for health
• ISBN-10: 1-119-01128-0 / 1119011280
• ISBN-13: 978-1-119-01128-6 / 9781119011286